Bruno Fang, MD
Hematology & Oncology · East Brunswick, NJNPI 1982692851
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 62 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 14.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $852 and has fallen 85.2% since, to $127 in 2025. That places this record below the midpoint for hematology & oncology clinicians in NJ, where the typical reported total is $2,686.
Across 62 payments — averaging $32.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Exelixis Inc.$285
- Daiichi Sankyo Inc.$145
- AstraZeneca$140
- Karyopharm Therapeutics Inc.$137
- E.r. Squibb & Sons, L.L.C.$128
- Epizyme, Inc.$125
- plus $1K from 31 others
Across 980 payments — averaging $8710.19 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$1.6M
- Janssen Research & Development, LLC$1.4M
- Exelixis Inc.$1.2M
- Daiichi Sankyo Inc.$1.1M
- AstraZeneca$540K
- AbbVie$449K
- plus $2.2M from 22 others
What the payments were for
- Food & beverage$2,02399%
- Education$121%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Exelixis Inc. | 2 | $285 |
| Daiichi Sankyo Inc. | 2 | $145 |
| AstraZeneca(2 entities) | 2 | $140 |
| Karyopharm Therapeutics Inc. | 2 | $137 |
| E.r. Squibb & Sons, L.L.C. | 3 | $128 |
| Epizyme, Inc. | 1 | $125 |
| Blueprint Medicines Corporation | 3 | $123 |
| ASD Specialty Healthcare, LLC | 2 | $117 |
| Bristol Myers Squibb | 5 | $87 |
| Genentech USA, Inc. | 4 | $70 |
| Mirati Therapeutics, Inc. | 3 | $63 |
| Regeneron Healthcare Solutions, Inc. | 2 | $46 |
| Novartis | 2 | $44 |
| GSK | 2 | $37 |
| Pfizer | 2 | $36 |
| AbbVie | 2 | $35 |
| Avyxa Pharma, LLC | 1 | $33 |
| Gilead | 2 | $31 |
| Lilly USA, LLC | 2 | $27 |
| ADC Therapeutics America, Inc. | 1 | $21 |
| Sanofi | 1 | $21 |
| Eisai Inc. | 1 | $20 |
| Merck | 1 | $20 |
| Incyte Corporation | 1 | $19 |
| Astellas Pharma US Inc | 1 | $19 |
| Pharmaessentia USA Corporation | 1 | $19 |
| Johnson & Johnson | 1 | $19 |
| Stemline Therapeutics Inc. | 1 | $19 |
| Azurity Pharmaceuticals, Inc. | 1 | $19 |
| Pharmacosmos Therapeutics Inc. | 1 | $18 |
| CTI Biopharma Corp. | 1 | $18 |
| Beigene USA, Inc. | 1 | $17 |
| Ipsen Biopharmaceuticals, Inc | 1 | $17 |
| Jazz Pharmaceuticals Inc. | 1 | $17 |
| Telix Pharmaceuticals | 1 | $16 |
| Octapharma USA, Inc. | 1 | $15 |
| EMD Serono, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,036 in reported general payments places this provider in the 45th percentile of 362 hematology & oncology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 16 | $318,315 |
| AranespDarbepoetin Alfa In Polysorbat | 104 | $272,762 |
| RevlimidLenalidomide | 18 | $270,721 |
| Somatuline DepotLanreotide Acetate | 27 | $247,915 |
| BosulifBosutinib | 12 | $236,075 |
| Lupron DepotLeuprolide Acetate | 41 | $233,602 |
| AlecensaAlectinib Hcl | 12 | $222,645 |
| MekinistTrametinib Dimethyl Sulfoxide | 14 | $212,013 |
| NeulastaPegfilgrastim | 28 | $201,731 |
| IbrancePalbociclib | 12 | $187,552 |
| TafinlarDabrafenib Mesylate | 14 | $185,474 |
| ProcritEpoetin Alfa | 59 | $149,672 |
| NinlaroIxazomib Citrate | 12 | $139,574 |
| EliquisApixaban | 101 | $85,399 |
| XareltoRivaroxaban | 63 | $59,800 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerBosulif, Ibrance, Eliquis, Nyvepria, Aromasin | $36 | $569,402150 claims |
| NovartisMekinist, Tafinlar, Sandostatin Lar Depot | $44 | $441,61441 claims |
| Incyte CorporationJakafi | $19 | $318,31516 claims |
| Bristol Myers SquibbRevlimid | $87 | $270,72118 claims |
| Ipsen Biopharmaceuticals, IncSomatuline Depot | $17 | $247,91527 claims |
| AbbVieLupron Depot | $35 | $233,60241 claims |
| Genentech USA, Inc.Alecensa | $70 | $222,64512 claims |
| Johnson & JohnsonProcrit, Xarelto | $19 | $209,472122 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 362 hematology & oncology providers in New Jersey.
Other hematology & oncology in East Brunswick
- Aamer FarooqEast Brunswick$17K
- Robert SpiegelWestfield$864K
- Amit PatelJersey City$770K
- Joshua StraussSpringfield$739K
- Charles FarberMorristown$609K
- Michael ScolaMorristown$506K
- Eshan PatelSomerville$420K
- Arturo Loaiza-BonillaPennington$406K
- Ashish ShahSpringfield$394K
- Carl HenningsonManasquan$349K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.